Sofinnova Investments Inc. Acquires Shares of 1,104,274 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Posted by Brenda Bartman on Jun 16th, 2026

Sofinnova Investments Inc. purchased a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 1,104,274 shares of the company’s stock, valued at approximately $27,618,000. Centessa Pharmaceuticals makes up approximately 1.1% of Sofinnova Investments Inc.’s portfolio, making the stock its 29th biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the last quarter. Maverick Capital Ltd. purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $41,110,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Centessa Pharmaceuticals by 20.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after purchasing an additional 1,449,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of Centessa Pharmaceuticals in the second quarter worth about $16,052,000. Finally, Commodore Capital LP grew its holdings in Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after acquiring an additional 930,711 shares during the period. Institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CNTA. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Guggenheim cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $41.33.

Get Our Latest Report on CNTA

Centessa Pharmaceuticals Trading Up 0.1%

NASDAQ:CNTA opened at $39.76 on Tuesday. The stock has a 50-day simple moving average of $39.64 and a 200-day simple moving average of $30.96. The stock has a market cap of $6.15 billion, a P/E ratio of -22.21 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $12.05 and a 1 year high of $40.26. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Company Profile

(Free Report)

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.